Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 13/20 | 0.66 |
| ▸ | INSR | P06213 | 6/20 | 0.66 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.64 |
| ▸ | JAK2 | O60674 | 3/20 | 0.63 |
| ▸ | SRC | P12931 | 3/20 | 0.63 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.63 |
| ▸ | IGF1R | P08069 | 4/20 | 0.60 |
| ▸ | JAK3 | P52333 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 5/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26361415 | 1.00 | ALK (0.66) | ALKINSRLRRK2JAK2SRC | |
| SCHEMBL24258116 | 0.93 | ALK (0.66) | ALKINSRLRRK2JAK2SRC | |
| SCHEMBL24258110 | 0.93 | ALK (0.67) | ALKINSRLRRK2JAK2SRC | |
| SCHEMBL24258141 | 0.93 | ALK (0.67) | ALKINSRLRRK2JAK2SRC | |
| SCHEMBL26361392 | 0.89 | ALK (0.64) | ALKINSRLRRK2JAK2SRC | |
| SCHEMBL24258139 | 0.88 | ALK (0.63) | ALKINSRLRRK2JAK2SRC | |
| SCHEMBL26361813 | 0.88 | ALK (0.63) | ALKINSRLRRK2JAK2SRC | |
| SCHEMBL24258115 | 0.87 | ALK (0.66) | ALKINSRLRRK2JAK2SRC | |
| SCHEMBL24255302 | 0.83 | ALK (0.77) | ALKINSRLRRK2JAK2SRC | |
| SCHEMBL24258103 | 0.81 | JAK3 (0.68) | ALKINSRLRRK2JAK2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303499-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | NATIONAL INSTITUTES OF HEALTH | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303499-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNK2, TNNI3K | ALK 272/4885INSR 2495/4885LRRK2 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.